Bambusa Therapeutics Files for IPO To Fund Eczema Drug Trials
A ipo & listings development with market-wide reach.
· NDTV Profit
Started in 2024, Bambusa secured its lead drug candidates through its earlier acquisition of assets from a unit of BioNTech SE, the first to treat atopic dermatitis, commonly known as eczema, and the second to treat other inflammatory disorders including respiratory and allergic diseases.
The analysis
Listing activity is a read on risk appetite — a hot primary market usually means a confident secondary one.
Related coverage
Flipkart said to weigh $2 bn Esop buyout for current employees in early 2027 amid IPO uncertainty
Airtel Money Makes London Stock Exchange Debut; Biggest Listing In 5 Years
Nvidia-backed Firmus scraps $5 bn Australia IPO amid growing AI scrutiny
Zetwerk eyes ₹27,000 crore IPO valuation as over 30 investors weigh anchor book
Jio Platforms IPO: What does listing of Reliance Industries' company means for Airtel, Vodafone Idea, Indus Towers share